Abstract library

19 results for "Rodriguez-Laval".
#2795 Molecular Correlation of the Activity of Evofosfamide (EVO) in Combination with Sunitinib (SUN) in Pancreatic Neuroendocrine Tumors (pNETs) in the SUNEVO GETNE Trial
Introduction: MEN1, DAXX, ATRX, and PI3K/AKT/mTOR pathway genes are frequently mutated in pNETs. Sunitinib is approved and widely used in the metastatic setting but unfortunately, no validated predictive biomarker has been identified to guide therapy yet. The SUNEVO phase II trial of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumours (GETNE) trial combined the pro-drug of EVO under SUN-induced hypoxic conditions.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Dr. Enrique Grande
#2891 Bone Metastases and Skeletal Related Events in Patients with Neuroendocrine Neoplasms (NEN): The Role of Zoledronic Acid
Introduction: The incidence of bone metastases (BM) in patients with NENs is 12-25%, and skeletal related events (SREs) occur in up to 21% of affected cases. Data about the efficacy of bisphosphonates in NEN patients (pts) with BM are limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Dr Eleni Armeni
#2940 Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated, Grade 3 Neuroendocrine Carcinomas (NECs)
Introduction: Poorly differentiated, G3 NECs are associated with poor outcomes and have no effective treatment options apart from cytotoxic chemotherapy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: MD, PhD Victor Rodriguez-Freixinos
#3019 Incomplete Peptide Receptor Radionuclide Therapy Courses - Are We Selecting Our Patients Appropriately?
Introduction: As per recommendations, a Peptide Receptor Radionuclide Therapy (PRRT) with Lu-177 DOTATATE course usually consists of 4 cycles. Patients may discontinue a PRRT course early, either due to progression or toxicity. Limited data are available about predictive factors for PRRT early discontinuation.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Julian Gertner
Authors: Gertner J, Groves J, Aziz B, Miah L, ...
Keywords: prrt
#758 Cardiac Metastases in Neuroendocrine Tumors- Diagnosis, Management and Outcomes
Introduction: Common areas of metastases in neuroendocrine tumors (NET) include liver, lymph nodes and bone. Limited data are available for cardiac metastases (CM).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: DR Vincent Cheung
#761 Use of Molecular Imaging to Differentiate Neuroendocrine Tumors from Other Synchronous Primary Cancers: A Case Series
Introduction: Approximately 22% of neuroendocrine tumors (NET) co-exist with other cancers.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: DR Vincent Cheung
Keywords: NET, synchronous, PET, Gallium, FDG
#768 Long-Term Haematological and Renal Toxicity of 90Yttrium-DOTA-Octreotate in the Treatment of Advanced Neuroendocrine Tumors(NETs)
Introduction: Peptide receptor radiation therapy (PRRT) is an established treatment for advanced NETs. Renal/haematological toxicity are recognised adverse effects.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: DR VINCENT Cheung
#863 Assessment of Neuroendocrine Tumors' Heterogeneity with Combination of Molecular Imaging Studies
Introduction: Neuroendocrine tumors (NET) are heterogeneous neoplasms. The choice of the appropriate molecular imaging study for assessment of disease extent usually depends on tumor grade.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Roberta E Rossi
#941 Comparison of Radiolableled Somatostatin Analogues and (131) I-MIBG Treatment for the Management of Patients with Metastatic/Progressive Phaeochromocytomas and Paragangliomas
Introduction: Radionuclide therapy has been used to treat patients with progressive/metastatic paragangliomas (PGGs) and pheochromocytomas (PCCs). To date, there is no study comparing (131)I-MIBG and peptide receptor radionuclide treatment (PRRT) in those patients.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Christos Toumpanakis
#1106 Salvage Treatment with Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Advanced VIPomas and Severe Verner-Morrison Syndrome
Introduction: PRRT is an effective treatment option for advanced Neuroendocrine Tumours
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Clinical cases/reports
Presenting Author: Dr Mehmet Yalchin
Keywords: PRRT VIP